Valuation: Neothetics Inc

Market Cap 10.2L 9L 8L 8L 14.43L 9.78Cr 14.53L 1.01Cr 39.2L 5Cr 38.31L 37.49L 16Cr P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 5.54Cr 4.86Cr 4.59Cr 4.19Cr 7.84Cr 531.34Cr 7.89Cr 55Cr 21Cr 271.45Cr 21Cr 20Cr 872.41Cr EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 01/01/2018
Director of Finance/CFO 49 13/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
-3.63%-6.12% - - 10.2L
+0.13%+2.65%+65.61%+114.28% 1,05500Cr
+0.20%+0.46%+52.60%+69.24% 65TCr
-0.29%+0.14%+20.96%+70.93% 47TCr
-0.85%+0.98%+41.29%+44.38% 35TCr
+0.71%+4.08%+22.24%+29.51% 27TCr
+1.23%+0.42%+14.57%+12.13% 26TCr
+2.11%+7.51%+52.89%+55.37% 22TCr
+0.83%+0.55%+35.99%+101.70% 19TCr
0.00%-10.14%-29.94%-60.30% 17TCr
Average -0.04%+0.74%+30.69%+48.58% 40.43TCr
Weighted average by Cap. +0.02%+1.32%+41.54%+67.83%

Financials

2024 2025
Net sales 1.94Cr 1.7Cr 1.6Cr 1.46Cr 2.74Cr 185.58Cr 2.76Cr 19Cr 7.44Cr 95Cr 7.27Cr 7.11Cr 304.71Cr 2.02Cr 1.77Cr 1.67Cr 1.52Cr 2.85Cr 193.44Cr 2.87Cr 20Cr 7.75Cr 99Cr 7.58Cr 7.41Cr 317.62Cr
Net income -88.6L -77.75L -73.43L -66.92L -1.25Cr -85Cr -1.26Cr -8.79Cr -3.4Cr -43Cr -3.33Cr -3.25Cr -139.43Cr 4L 3L 3L 3L 6L 3.75Cr 6L 38.78L 15.02L 1.91Cr 14.68L 14.36L 6.15Cr
Net Debt 4.58Cr 4.02Cr 3.8Cr 3.46Cr 6.48Cr 439.35Cr 6.53Cr 45Cr 18Cr 224.46Cr 17Cr 17Cr 721.37Cr 5.44Cr 4.78Cr 4.51Cr 4.11Cr 7.69Cr 521.56Cr 7.75Cr 54Cr 21Cr 266.45Cr 20Cr 20Cr 856.35Cr
Logo Neothetics Inc
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
-